XOMA

XOMA ROYALTY CORPORATION

XOMA·98419J206·US·Common Stock·Healthcare - Biotechnology-Activist

XOMA (XOMA ROYALTY CORPORATION) is held by 57 institutional investors as of Q1 2026. Largest holders: MORGAN STANLEY ($53.4M), FMR LLC ($40.9M), BlackRock, Inc. ($20.3M). Net institutional sentiment: Bullish.

57
Holders
Avg rating(12 Elite)
$202.3M
Total Value
70% (62)
Fund Consensus
38 buying - 16 selling
XOMASmart Money Verdict
View all
Held by 57 funds
12 elite
Who's Trading
ActivistBVBIOTECHNOLOGY VALUE FUND L P20.7%May 18, 2026
ActivistWoodline Partners LPWoodline Partners LP5.4%May 15, 2026
ActivistLPLigand Pharmaceuticals Incorporated47.0%May 1, 2026
ActivistVAVanguard Capital Management5.2%Apr 30, 2026
ActivistBlackRock, Inc.BlackRock, Inc.5.4%Apr 27, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
InsiderHOHughes OwenBuy $2.5MDec 4, 2025
InsiderBMBURNS THOMAS M.Sell $155KSep 22, 2025
InsiderBMBURNS THOMAS M.Sell $553.95Sep 22, 2025
InsiderBMBURNS THOMAS M.Sell $552.15Sep 22, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Decreased
1.7M(-0.7%)$53.4M0.0%+83.02%
0
Increased
1.3M(+12.1%)$40.9M0.0%+69.84%
33
Increased
646,914(+5.8%)$20.3M0.0%+68.71%
30
Increased
640,001(+143.4%)$20.1M0.1%+73.19%
46
New
549,796$17.2M0.0%+73.14%
39
Increased
229,766(+3.7%)$7.2M0.0%+86.81%
28
New
204,920$6.4M0.0%+73.14%
38
Increased
193,148(+10.4%)$6.1M0.0%+102.77%
30
Increased
133,360(+207.7%)$4.2M0.0%+75.46%
43
New
98,638$3.1M0.0%+73.14%
37
Increased
93,490(+3.4%)$2.9M0.0%+105.28%
27
New
85,797$2.7M0.0%+73.14%
36
Increased
74,984(+9.7%)$2.4M0.0%+29.39%
29
Increased
72,533(+178.5%)$2.3M0.0%+71.57%
42
New
66,664$2.1M0.0%+73.14%
36
Increased
58,662(+176.3%)$1.8M0.0%+69.08%
42
New
28,894$906,4050.0%+73.14%
34
New
28,495$893,8880.0%+73.14%
34
Decreased
27,151(-7.6%)$851,7270.0%+97.80%
0
Increased
26,075(+168.4%)$817,9730.0%+71.54%
40

Showing 1-20 of 62

1 / 4

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used